KRAS+ NSCLC

Cecilia BrownKRAS+ NSCLC | February 26, 2025

Researchers evaluated if demographics, clinical characteristics, and outcomes varied between those with KRAS G12C and G12D.

Cecilia BrownKRAS+ NSCLC | January 14, 2025

A team integrating clinical, dual-energy spectral computed tomography, and radiomics features into a predictive model.

Cecilia BrownKRAS+ NSCLC | January 9, 2025

Glecirasib, also known as JAB-21822, is an oral, covalent KRAS G12C inhibitor.

Cecilia BrownNon-Small Cell Lung Cancer | December 30, 2024

The foundation's 2024 Scientific Grant Program awards mark the "largest single-year investment in its history.”

Katie KoskoASCO 2024 | July 30, 2024

Researchers say the results support the evaluation of the treatment in the phase 3 CodeBreaK 202 trial.

Mary GreccoESMO TAT 2024 | April 25, 2024

MK-1084 as monotherapy and in combination with pembrolizumab is effective in patients with NSCLC.

Mary GreccoNACLC 2023 | March 25, 2024

Results of a study that evaluated the impact of comprehensive versus limited NGS for advanced NSCLC.

Eileen Koutnik-FotopoulosNon-Small Cell Lung Cancer | January 26, 2024

Researchers examined the demographic and clinical outcomes in patients with KRAS-mutated tumors, using patients with NSCLC.

Kaitlyn KoskoEGFR+ NSCLC | January 25, 2024

Patients of Hispanic/Latino ethnicity have a greater prevalence of certain lung cancer driver mutations.